FDA Deregulates AI Wearables and Health Devices: What It Means for Exhibitors at HIMSS, ViVE, and BIO 2026

On January 6, 2026, the U.S. Food and Drug Administration released a pair of updated guidance documents that could fundamentally reshape the digital health landscape—and, by extension, the trade show floor at every major healthcare technology event this year. The new guidance eases regulation of AI-powered clinical decision support (CDS) software and consumer wearable devices, creating what many industry analysts are already calling the most significant regulatory shift in health technology since the 21st Century Cures Act of 2016.

For exhibitors preparing for HIMSS 2026 in Las Vegas (March 9–12), ViVE 2026 in Los Angeles (February 22–25), BIO 2026, MEDICA, and INTERPHEX, this is not just a policy headline. It is a fundamental change in what you can say on a banner, what you can demonstrate in a booth, how you position your product to buyers, and how your regulatory and legal teams need to prepare for the show floor conversations that will define your pipeline for the rest of the year.

This article breaks down exactly what the FDA changed, why it matters, what the state-level regulatory patchwork means for your compliance posture, and—most critically—how to translate all of it into concrete exhibitor strategy at the biggest health tech trade shows of 2026.

What the FDA Actually Changed: The Two Guidance Documents Explained

To understand the strategic implications, you first need to understand the regulatory mechanics. The FDA released two distinct but related guidance documents on January 6, 2026. Each addresses a different product category, but together they signal a coherent philosophical shift in how the agency plans to oversee AI-driven health technology.

The 2026 Clinical Decision Support (CDS) Guidance

The first document updates the FDA's enforcement discretion policy for clinical decision support software. Under the previous framework, CDS tools that used artificial intelligence—particularly those incorporating machine learning models or generative AI features—often fell into a regulatory gray area. Many companies were uncertain whether their AI-powered CDS tools required formal FDA clearance (typically through the 510(k) pathway) or whether they qualified for the CDS exemption carved out by the 21st Century Cures Act.

The 2026 CDS guidance expands enforcement discretion to explicitly cover AI-driven clinical decision support, including products with generative AI features that provide clinically appropriate recommendations. The critical condition: clinicians must be able to independently review and verify the underlying logic of those recommendations. In regulatory parlance, the software must remain a "tool" that supports the clinician's judgment rather than replacing it.

This is a major expansion. Previously, many companies with AI-driven CDS tools were either filing 510(k) applications out of an abundance of caution or limiting their marketing claims to stay safely within the old enforcement discretion boundaries. The new guidance gives companies considerably more room to describe their AI capabilities without triggering formal device classification.

The 2026 Consumer Wellness Wearables Guidance

The second document addresses consumer-facing wearable devices. Under previous FDA policy, wearables that measured physiological parameters like blood pressure, blood oxygen saturation (SpO2), or glucose levels were generally considered medical devices subject to premarket review. This created a significant barrier for consumer wearable companies that wanted to offer health-monitoring features without going through the expensive and time-consuming FDA clearance process.

The 2026 wellness guidance expands the category of exempt consumer wearables to include devices that report blood pressure trends, oxygen saturation levels, and glucose-related signals. The key distinction is that these devices must present data as wellness information—trends, patterns, and general health signals—rather than as diagnostic or clinical measurements.

For the wearable technology industry, this is transformative. Companies that have been developing non-invasive glucose monitoring, continuous blood pressure tracking, or advanced pulse oximetry for consumer devices now have a significantly clearer regulatory pathway. They can bring products to market faster, make broader wellness claims in their marketing, and—critically for trade show exhibitors—demonstrate these capabilities in booth environments without the legal ambiguity that previously constrained their messaging.

Commissioner Makary's "Silicon Valley Speed" Mandate and What It Signals

The guidance documents did not arrive in a vacuum. FDA Commissioner Marty Makary, who has been vocal about modernizing the agency since his appointment, used his appearance at CES 2026 to frame the regulatory changes as part of a broader institutional transformation. His statement that the FDA needs to move "at Silicon Valley speed" was not just a soundbite—it reflects a genuine strategic reorientation that exhibitors need to internalize.

"The FDA needs to move at Silicon Valley speed. We cannot continue applying a 20th-century regulatory framework to 21st-century technology. Our job is to protect the public, and the best way to do that with AI is through smart post-market monitoring, not by creating bottlenecks that keep safe, effective technology away from the people who need it." — FDA Commissioner Marty Makary, CES 2026 keynote, January 6, 2026

Makary's comments signal three things that matter for exhibitors. First, the FDA is actively working on a new regulatory framework that emphasizes post-market monitoring via big data analytics rather than traditional premarket review. This means the entire compliance conversation is shifting from "Did you get clearance?" to "How are you monitoring real-world performance?" Second, the agency wants to be seen as an enabler of innovation, not a barrier. Third, the pace of regulatory change is likely to accelerate, meaning the guidance released in January could be followed by additional clarifications or expansions throughout 2026.

For trade show exhibitors, this creates both an opportunity and an obligation. The opportunity is to position your company as one that is riding the wave of regulatory modernization, bringing innovative products to market faster because the FDA is creating space for you to do so. The obligation is to ensure your messaging accurately reflects the current state of regulation—not where you hope it will be in six months.

The State-Level Patchwork: 250+ Bills Across 34 States

While the federal regulatory landscape is becoming more permissive, the state-level picture is moving in a more complex direction. As of early 2026, over 250 AI-related health bills have been introduced across more than 34 states, creating a patchwork of compliance requirements that exhibitors must navigate carefully.

These state bills cover a wide range of issues, including AI transparency requirements, algorithmic bias auditing mandates, patient data privacy protections, informed consent requirements for AI-assisted care, and liability frameworks for AI-driven clinical decisions. Some states are taking approaches that are more restrictive than federal policy, while others are creating innovation-friendly regulatory sandboxes.

For exhibitors, this state-level complexity has several practical implications on the show floor:

• Marketing claims must be jurisdiction-aware. A claim that is perfectly compliant with FDA guidance may run afoul of state-level AI transparency requirements in California, New York, or Illinois. Your booth materials need to account for the fact that your buyers come from different regulatory environments.
• Sales teams need compliance briefings. Booth staff must understand not just what the FDA guidance says, but how state-level requirements may affect the buyer's ability to deploy your product. A hospital system in Texas may face different regulatory considerations than one in Massachusetts.
• Compliance becomes a selling point. Companies that can demonstrate multi-jurisdictional compliance have a competitive advantage. If you can show a buyer that your AI wearable or CDS software meets not just federal requirements but also the toughest state-level standards, you differentiate yourself from competitors who can only speak to FDA exemption.
• Legal review of booth materials is essential. Every banner, brochure, demo script, and slide deck should be reviewed by regulatory counsel who understands both the federal guidance and the state-level landscape. The cost of a compliance misstep at a show attended by 40,000 healthcare professionals is not just a fine—it is reputational damage that can take years to repair.

HIMSS 2026: The Main Stage for Digital Health Exhibitors

HIMSS 2026 runs March 9–12 at the Las Vegas Convention Center, and with over 40,000 expected attendees, it is the single most important venue for digital health companies to capitalize on the FDA's new regulatory posture. If you are exhibiting at HIMSS this year, the deregulation news should reshape virtually every aspect of your show strategy.

Booth Messaging Strategy for HIMSS 2026

The first and most important adjustment is your booth messaging. Before January 6, many exhibitors with AI-powered CDS tools or wellness wearables were using cautious, hedged language—"pending regulatory clearance," "designed to support," "wellness information only." The new guidance allows you to be significantly more direct about what your product does, as long as you stay within the boundaries of the exemptions.

For CDS software exhibitors, this means you can now prominently feature your AI and generative AI capabilities in your booth messaging. Instead of burying AI features in technical spec sheets, put them on your main banner. Instead of describing your tool as "decision support software," you can describe it as "AI-powered clinical decision support" and explain how clinicians can verify the underlying logic. The transparency requirement becomes a feature, not a limitation—frame it as "explainable AI" or "clinician-verifiable recommendations."

For wearable device exhibitors, the change is even more dramatic. If your device measures blood pressure trends, SpO2 levels, or glucose-related signals, you can now demonstrate these features openly on the show floor as consumer wellness capabilities. Set up interactive demo stations where attendees can try the device and see real-time wellness data. This was a minefield six weeks ago; now it is your primary engagement tool.

Demo Strategy: Show, Don't Just Tell

The expanded enforcement discretion fundamentally changes what you can demonstrate at HIMSS. Previously, showing a live AI-generated clinical recommendation in a booth could raise questions about whether you were marketing an uncleared device. Now, as long as your demo clearly shows the clinician-verifiable logic pathway, you are operating within the guidance.

Consider structuring your HIMSS demos around what we call the "transparency loop":

1. Input. Show the data going into the AI system—patient records, lab results, imaging data, or wearable sensor streams.
2. Process. Demonstrate the AI's reasoning chain. This is where you satisfy the "clinician can verify the underlying logic" requirement while also showcasing the sophistication of your technology.
3. Output. Present the recommendation, risk score, or clinical insight, clearly labeled as decision support.
4. Verify. Show how a clinician would review, modify, or override the recommendation. This step is both a compliance requirement and a trust-building moment with your audience.

This four-step demo structure accomplishes two things simultaneously: it satisfies the regulatory framework by showing clinician oversight, and it gives buyers confidence that your product fits into their clinical workflows without disrupting clinician autonomy.

Meeting Strategy: Who to Target at HIMSS 2026

The FDA news changes the buyer landscape at HIMSS in important ways. Before the guidance update, many health system CIOs and CTOs were hesitant to evaluate AI-powered CDS tools because of regulatory uncertainty. That barrier has been significantly lowered. This means exhibitors should expect a broader range of decision-makers to be actively shopping for AI-driven solutions at HIMSS 2026.

Prioritize meetings with these roles:

• Chief Medical Information Officers (CMIOs). They are the clinical champions who will evaluate whether your AI tool meets the "clinician-verifiable" standard. They are also the ones most excited about the new guidance because it accelerates their digital transformation roadmaps.
• VP of Digital Health / Innovation. These leaders have been waiting for regulatory clarity to greenlight AI initiatives. The January guidance gives them the cover they need to move forward, and they will be at HIMSS actively evaluating solutions.
• Chief Compliance Officers. Interestingly, the deregulation may increase demand from compliance teams, not decrease it. They need to understand the new boundaries, and they will be looking for vendors who can clearly articulate what is and is not covered by the guidance.
• Procurement and Supply Chain Leaders. With the regulatory pathway clearer, purchasing decisions can move faster. These buyers will be looking for pricing, implementation timelines, and ROI data.

Thought Leadership Opportunities at HIMSS 2026

HIMSS offers extensive programming, and the FDA guidance will dominate multiple tracks. If you have not already submitted speaking proposals or panel participation requests, reach out to the organizers immediately. Sessions on regulatory changes, AI in clinical workflows, and wearable technology integration will be standing-room-only this year. Even if you cannot secure a formal speaking slot, consider hosting a satellite event, breakfast briefing, or evening reception focused on "What the FDA Guidance Means for [Your Product Category]."

Position your company's regulatory and clinical leadership as thought leaders, not just your sales team. Buyers at HIMSS want to know that you understand the regulatory nuances, not just that you have a product to sell. A 30-minute breakfast briefing led by your Chief Medical Officer and VP of Regulatory Affairs, explaining how your company has adapted its product and go-to-market strategy in response to the guidance, will generate more qualified leads than a week of badge-scanning on the exhibit floor.

ViVE 2026: The Innovation Showcase That Sets the Tone

ViVE 2026 runs February 22–25 in Los Angeles, which means it arrives before HIMSS and serves as the opening act for the spring health tech trade show season. With over 9,000 expected attendees, ViVE is smaller and more intimate than HIMSS, but its audience skews heavily toward innovation leaders, digital health investors, and early-stage companies—exactly the constituency most directly affected by the FDA's deregulation moves.

ViVE Exhibitor Strategy: Lead with the Regulatory Narrative

At ViVE, the audience is looking for what is new, what is next, and what is possible. The FDA guidance gives you a powerful narrative framework: "The regulatory barriers that were holding back our technology have been removed. Here is what we can now do." This is a story that resonates deeply with the ViVE audience, which includes venture capitalists evaluating digital health investments, health system innovation officers scouting new solutions, and startup founders looking for partnership and acquisition opportunities.

Your ViVE booth should tell a before-and-after story. Before the January guidance, your product was constrained in these specific ways. After the guidance, here is the expanded set of capabilities, use cases, and market opportunities. This narrative works whether you are a startup with a single AI-powered wearable or a large enterprise software company with a suite of CDS tools.

Investor Meetings at ViVE: The Regulatory Tailwind Story

If you are a startup or growth-stage company exhibiting at ViVE, the FDA guidance is the single best thing that could have happened to your fundraising narrative. Investors in digital health have been cautious about regulatory risk for years. The January guidance dramatically de-risks the AI health technology category, and investors know it.

Prepare an investor-specific version of your pitch that explicitly addresses the regulatory shift. Quantify how the guidance changes your timeline to market, your total addressable market, and your competitive position. If your product was previously in a regulatory gray area and is now clearly covered by enforcement discretion, that is a material change in your risk profile that should be reflected in your valuation conversations.

ViVE's networking events, hallway conversations, and intimate session formats are ideal for these conversations. Book investor meetings well in advance—the competition for face time with top-tier health tech VCs at ViVE is intense, and the FDA news means every AI health company will be trying to have the same conversation.

ViVE Panel Strategy: Own the Conversation

ViVE's programming tends to be more forward-looking and debate-oriented than HIMSS. Propose or join panels that address the harder questions around the FDA guidance: What happens when state regulations conflict with federal enforcement discretion? How should companies handle the post-market monitoring requirements that Commissioner Makary has signaled? What are the liability implications if an AI recommendation covered by enforcement discretion leads to patient harm?

These are the questions that sophisticated buyers and investors are asking, and the companies that can engage with them credibly will stand out from those that simply celebrate the deregulation without acknowledging the complexity.

BIO 2026, MEDICA, and INTERPHEX: Extending the Strategy Beyond Health IT

While HIMSS and ViVE are the primary venues for digital health exhibitors, the FDA guidance has implications that extend to biotech, pharmaceutical, and medical device trade shows as well.

BIO 2026: Where Wearables Meet Drug Development

The BIO International Convention is traditionally focused on biotechnology and pharmaceutical innovation, but the convergence of wearable technology with drug development is creating new exhibition opportunities. AI-powered wearables that can monitor biomarkers like blood pressure, glucose-related signals, and oxygen saturation are increasingly relevant to clinical trial design, patient monitoring during drug studies, and companion diagnostic development.

If you are exhibiting at BIO 2026, position your wearable technology as a clinical trial enablement tool. The FDA's expansion of wellness exemptions means your device can capture a wider range of physiological data without requiring separate device clearance for each parameter. For pharmaceutical companies designing decentralized clinical trials, this is a compelling value proposition: they can use consumer-grade wearables to collect real-world data from study participants without navigating complex device regulatory pathways for each sensor modality.

Your BIO booth messaging should emphasize data quality, interoperability with clinical trial management systems, and regulatory simplicity. Pharmaceutical buyers care about regulatory risk in their own domain—the last thing they want is to add device regulatory complexity on top of their drug approval process. Show them that your wearable is exempt, that the data it produces is reliable, and that it integrates with their existing infrastructure.

MEDICA and INTERPHEX: The Manufacturing and Supply Chain Angle

MEDICA and INTERPHEX serve audiences focused on medical device manufacturing, packaging, and supply chain management. The FDA guidance affects these audiences in a less obvious but equally important way: by expanding the category of exempt wellness devices, the guidance is expected to significantly increase demand for wearable device components, sensors, and manufacturing services.

Companies that manufacture MEMS sensors, flexible electronics, biocompatible materials, or wearable device enclosures should update their trade show messaging to reflect the expanded market opportunity. If your component or manufacturing service enables blood pressure sensing, pulse oximetry, or non-invasive glucose monitoring, the FDA guidance has just expanded your addressable market.

At MEDICA and INTERPHEX, lead with the market growth story. The deregulation of consumer wellness wearables means more companies will be bringing these devices to market, more quickly, and they will need manufacturing partners who can scale. Position your company as the supply chain partner that understands both the regulatory landscape and the manufacturing requirements for these newly exempt device categories.

The Post-Market Monitoring Shift: A New Compliance Conversation for the Booth

One of the most significant strategic implications of the FDA guidance is the emerging shift from premarket review to post-market monitoring. Commissioner Makary has explicitly stated that the agency is developing a new regulatory framework emphasizing post-market surveillance via big data analytics. This is not just a policy preference—it is a fundamental reorientation of how health technology will be regulated going forward.

"The future of device regulation is not a stack of premarket submissions sitting on a reviewer's desk. It is a real-time data infrastructure that can detect safety signals, monitor performance trends, and enable rapid intervention when problems emerge. That is where we are going, and that is where industry should be investing." — Senior FDA official on the agency's post-market monitoring vision

For exhibitors, this shift creates a new category of conversation on the trade show floor. Buyers are not just asking "Is your product cleared?" anymore. They are asking "How do you monitor performance after deployment? What data do you collect? How do you detect and respond to safety signals? What is your real-world evidence strategy?"

Companies that can answer these questions credibly have a significant competitive advantage. Consider adding a "post-market monitoring" section to your booth experience—a screen or kiosk that shows your real-world data dashboard, your safety monitoring protocols, and your continuous improvement process. This demonstrates regulatory maturity and builds buyer confidence in a way that a 510(k) clearance letter never could.

Building a Post-Market Data Strategy for Show Floor Conversations

To prepare for these conversations at HIMSS, ViVE, and beyond, develop a concise one-pager that addresses these questions:

• What real-world performance data does your product collect?
• How is that data analyzed for safety signals and performance trends?
• What is your process for responding to identified issues?
• How do you share performance data with healthcare providers and regulators?
• What role does AI play in your post-market monitoring (creating an interesting recursive compliance story for AI-powered products)?

This one-pager should be available in both print and digital formats, and every member of your booth staff should be able to walk through it confidently. It is the kind of detail-oriented, compliance-aware material that separates serious players from companies that are just riding the deregulation hype wave.

Practical Exhibitor Checklist: Preparing for the Post-Guidance Show Season

With ViVE just days away and HIMSS a month out, exhibitors need to move quickly to capitalize on the FDA guidance. Here is a comprehensive checklist for trade show preparation in light of the regulatory changes.

Messaging and Collateral (Complete by February 15)

• Review all booth banners, posters, and signage for regulatory language that is now unnecessarily conservative. Update claims to reflect expanded enforcement discretion where appropriate.
• Update product brochures and sell sheets to prominently feature AI capabilities and newly exempt wellness parameters.
• Create a regulatory summary document—a concise explainer of the January 6 guidance and what it means for your product—that can be given to interested buyers.
• Develop jurisdiction-specific talking points for booth staff that account for state-level AI health regulations in key markets (California, New York, Illinois, Texas, Massachusetts).
• Have all updated materials reviewed by regulatory counsel before printing or deploying.

Demo and Experience Design (Complete by February 18)

• Redesign booth demos to showcase AI reasoning chains and clinician-verifiable logic pathways (the "transparency loop" described above).
• For wearable exhibitors: set up hands-on demo stations where attendees can experience real-time blood pressure, SpO2, or glucose signal monitoring.
• Prepare demo scenarios that explicitly show clinician override capabilities for CDS tools.
• Build a post-market monitoring visualization into your demo flow.
• Test all demo equipment and software in simulated show floor conditions (Wi-Fi congestion, noise, varied lighting).

Staff Training (Complete by February 20)

• Brief all booth staff on the January 6 guidance—what it says, what it does not say, and what remains ambiguous.
• Train staff on the state-level regulatory patchwork and how to handle questions about compliance in specific jurisdictions.
• Prepare responses for the three most likely challenging questions: "Is your product FDA-cleared?" (it may not need to be), "What about state regulations?" (here is our multi-jurisdictional compliance approach), and "What happens if the guidance changes?" (here is our regulatory contingency plan).
• Role-play demo scenarios with staff, including handling objections from skeptical clinicians and compliance officers.
• Ensure at least one person on each booth shift has deep regulatory knowledge and can handle complex compliance questions.

Meeting and Networking Preparation (Ongoing)

• Update your meeting request templates to reference the FDA guidance as a reason for connecting.
• Identify and prioritize the specific roles most affected by the guidance (CMIOs, VP Digital Health, compliance officers) in your target account list.
• For ViVE: schedule investor meetings and prepare the regulatory-tailwind version of your pitch.
• For HIMSS: submit late-breaking session proposals or reach out to organizers about participating in panels on AI regulation.
• Plan satellite events, dinners, or breakfast briefings focused on the regulatory changes.

Competitive Dynamics: How the Guidance Reshapes the Exhibit Hall

The FDA guidance does not affect all exhibitors equally, and understanding the competitive dynamics is essential for positioning your company effectively.

Winners: AI-Native Companies

Companies that have built their products around AI from the ground up are the biggest beneficiaries of the guidance. They have been constrained by regulatory uncertainty, and the expanded enforcement discretion unleashes their full capabilities. These companies will be the most aggressive in updating their booth messaging and demos, and they will dominate the AI-focused sessions at HIMSS and ViVE. If you are in this category, the guidance is your moment—lean into it fully.

Challengers: Traditional Health IT Companies Adding AI

Established health IT companies that have been adding AI features to their existing platforms face a more nuanced situation. The guidance helps them by clarifying the regulatory pathway for their AI additions, but they may struggle to compete with the AI-native companies on the "innovation" narrative. Their advantage is their existing installed base and customer relationships. At trade shows, they should frame their AI capabilities as low-risk enhancements to trusted platforms, rather than trying to out-innovate the startups on pure AI capability.

Disrupted: Companies That Relied on Regulatory Barriers

Some companies in the health technology space have benefited from the regulatory complexity that kept competitors out of the market. If your competitive moat was that you had FDA clearance and your competitors did not, the expanded enforcement discretion has just lowered that moat. These companies need to rapidly identify new differentiation points—data quality, clinical validation, integration depth, customer support—and reposition their show floor messaging accordingly.

New Entrants: Consumer Electronics Companies

The wellness wearable guidance is likely to attract consumer electronics companies that have been eyeing the health market but were deterred by regulatory requirements. Expect to see new exhibitors at HIMSS and ViVE from the consumer electronics world, bringing products that leverage the expanded wellness exemptions. Established health tech exhibitors should prepare for increased competition and noise on the show floor, and ensure their messaging clearly differentiates clinical-grade solutions from consumer wellness products where that distinction matters.

Legal Landmines on the Show Floor: What Not to Say

While the guidance expands what exhibitors can claim, it does not eliminate all restrictions. Here are the most common mistakes exhibitors are likely to make in the aftermath of the deregulation news, and how to avoid them.

Mistake 1: Claiming FDA "Approval" When You Have Enforcement Discretion

Enforcement discretion is not the same as FDA clearance or approval. If your product falls under the expanded enforcement discretion, you cannot say it is "FDA-approved" or "FDA-cleared." The accurate statement is that your product falls within the FDA's enforcement discretion policy for CDS software or consumer wellness devices. This is an important distinction that booth staff must understand and communicate precisely.

Mistake 2: Extending Claims Beyond the Guidance Boundaries

The CDS guidance covers AI that provides clinically appropriate recommendations where clinicians can verify the underlying logic. If your AI system operates autonomously without clinician oversight—for example, an AI that automatically adjusts medication dosing without a clinician in the loop—the new guidance may not cover you. Similarly, the wellness wearable guidance covers trend data and general health signals, not diagnostic claims. Saying your wearable "diagnoses hypertension" rather than "tracks blood pressure trends" crosses a line that the guidance did not move.

Mistake 3: Ignoring State-Level Requirements

As discussed above, the state-level regulatory patchwork is real and growing. An exhibitor who confidently tells a California hospital system that their AI tool is "fully deregulated" may be ignoring California's own AI transparency and algorithmic accountability requirements. Train your booth staff to qualify their regulatory claims by jurisdiction and to direct complex compliance questions to your regulatory affairs team.

Mistake 4: Overpromising on the Post-Market Framework

Commissioner Makary has signaled a move toward post-market monitoring, but the full framework has not been published yet. Do not tell buyers that "the FDA has replaced premarket review with post-market monitoring" because that is not yet the case. The accurate framing is that the agency is moving in that direction and that your company is preparing for it. Overpromising on the regulatory trajectory can erode trust when the full framework does not match expectations.

The International Dimension: MEDICA, Global Buyers, and Regulatory Arbitrage

The FDA's moves do not exist in isolation. International buyers at U.S. trade shows, and U.S. exhibitors at international shows like MEDICA, need to understand how the FDA guidance interacts with regulatory frameworks in other jurisdictions.

The European Union's AI Act, which is in the process of being implemented, takes a significantly different approach to AI in healthcare. The EU framework is more prescriptive about risk classification, transparency requirements, and conformity assessments. Similarly, regulatory frameworks in China, Japan, South Korea, and other major markets have their own approaches to AI health technology regulation.

For exhibitors at MEDICA and other international shows, the FDA guidance creates an interesting positioning opportunity: the U.S. market is now more accessible for AI health technology than many other major markets. This can be used to attract international buyers who want to enter or expand in the U.S. market, and to position the U.S. as a favorable regulatory environment for product launches.

Conversely, exhibitors targeting international markets at U.S. shows should be careful not to assume that the FDA's permissive stance applies globally. Prepare market-specific regulatory summaries for your key international target markets and ensure your booth staff can speak to the regulatory landscape in each.

Long-Term Strategic Implications: What Comes After the Guidance

The January 2026 guidance is not the end of the story. It is the beginning of a multi-year regulatory transformation that will continue to reshape the health technology trade show landscape. Here is what exhibitors should be watching for and preparing for in the medium term.

The Post-Market Monitoring Framework

Commissioner Makary has made clear that the FDA is developing a comprehensive post-market monitoring framework for AI health technology. When this framework is published—likely later in 2026 or in 2027—it will create new compliance requirements, new data infrastructure demands, and new business opportunities. Companies that start building their post-market monitoring capabilities now will have a head start when the framework drops.

State-Level Regulatory Convergence (or Divergence)

The 250+ state-level AI health bills currently in play will evolve over the next 12–24 months. Some will become law, others will be revised or abandoned. The key question is whether states will converge toward a set of common requirements (which would simplify compliance) or continue to diverge (which would increase complexity). Exhibitors should track the state-level landscape actively and update their trade show messaging as the picture becomes clearer.

The Liability Question

As AI health technology moves from the regulatory gray area into the mainstream, the question of liability will become increasingly urgent. Who is responsible when an AI-powered CDS tool provides a recommendation that leads to patient harm? The clinician who followed the recommendation? The company that built the tool? The health system that deployed it? These questions are unresolved, and they will be a major topic of conversation at trade shows throughout 2026 and beyond. Exhibitors should prepare thoughtful positions on liability allocation and be ready to discuss them with buyers.

Convergence of Consumer and Clinical Grade

The wellness wearable guidance blurs the line between consumer and clinical-grade devices. Over time, this line is likely to blur further as consumer wearable data quality improves and as the FDA develops frameworks for using consumer-generated data in clinical settings. Exhibitors should watch for opportunities to position their products at the intersection of consumer and clinical markets—a space that is likely to grow rapidly as the regulatory barriers between the two continue to erode.

Show Floor Execution: Tactical Tips for Maximum Impact

Beyond strategy, there are concrete tactical decisions that exhibitors need to make to maximize the impact of the FDA guidance at upcoming trade shows.

Signage and Visual Design

Update your main banner or backdrop to reference the regulatory shift. Language like "Now with expanded FDA enforcement discretion" or "AI-powered clinical decision support—no 510(k) required" is attention-grabbing and immediately communicates that your company is at the forefront of the regulatory wave. Just ensure that any claims are accurate and counsel-approved.

Lead Qualification Questions

Update your lead qualification scripts to include questions about the buyer's awareness of and response to the FDA guidance. "Have you updated your AI strategy in light of the January FDA guidance?" is a powerful opening question that immediately establishes relevance and positions your booth as a source of insight, not just a product pitch. It also helps you quickly identify the buyers who are most actively evaluating solutions and are therefore most likely to convert.

Follow-Up Strategy

Plan your post-show follow-up around the regulatory narrative. Send attendees a curated brief on the FDA guidance, a summary of how your product is positioned within the new framework, and an invitation to a deeper regulatory strategy conversation. This kind of value-added follow-up has dramatically higher response rates than a generic "Great meeting you at HIMSS" email.

Social Media and Content Strategy

Use your presence at HIMSS and ViVE to create content around the regulatory shift. Live-tweet key sessions, post video commentary from your booth, and publish daily show recaps that connect the exhibit hall energy to the broader FDA narrative. This content extends your show floor presence to the thousands of industry professionals who are following the shows remotely and positions your company as a thought leader in the regulatory conversation.

Conclusion: The Show Floor Is the First Battleground

The FDA's January 6, 2026 guidance documents are the most significant regulatory development in health technology in a decade. They lower barriers to market, expand what companies can claim and demonstrate, shift the compliance conversation from premarket to post-market, and inject new competitive dynamics into an already fast-moving industry.

But regulatory changes do not translate into business outcomes on their own. They translate into business outcomes on the trade show floor, in the meetings, demos, and conversations that turn regulatory shifts into pipeline, partnerships, and revenue. The companies that win in 2026 will not just be the ones with the best AI technology or the most favorable regulatory position. They will be the ones that translate those advantages into compelling show floor experiences at HIMSS, ViVE, BIO, MEDICA, and INTERPHEX.

ViVE 2026 is eleven days away. HIMSS 2026 is less than a month out. The time to update your booth strategy, retrain your staff, revise your collateral, and rethink your meeting targets is now. The FDA has opened the door. It is up to exhibitors to walk through it—confidently, compliantly, and strategically.